Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use
This narrative review (2026) examines placebo-controlled single-dose studies of MDMA (75 to 125 mg) in healthy volunteers and finds that it acutely increases mood, empathy, trust and prosocial feelings, while causing temporary memory impairment and modest declines in motor coordination and cognitive flexibility. It also notes that post-acute fatigue and low mood can occur, and that MDMA may complicate trial blinding and expectancy in psychotherapy studies.
Authors
- Johannes Ramaekers
- Kim Kuypers
- Franz Vollenweider
Published
Abstract
MDMA's history spans military experimentation, recreational use, and clinical trials for PTSD treatment, reflecting both promise and controversy. While studies in heavy users suggested possible neurotoxicity, evidence remains inconclusive. Clinical trials show that one to three sessions of MDMA-assisted psychotherapy can alleviate PTSD symptoms, yet regulators have criticized inadequate reporting of (positive) adverse events. To clarify safety, this narrative review examines placebo-controlled single-dose studies in healthy volunteers, focusing on MDMA's acute and subacute effects on subjective state and neurocognitive function relevant to therapeutic applications. Single doses of 75-125 mg enhance mood, empathy, trust, arousal, and prosocial feelings through monoamine reuptake inhibition and release. Post-acutely, transient monoamine depletion may cause fatigue and low mood. During intoxication, MDMA transiently impairs memory encoding via increased 5-HT signaling and 5-HT2A activation but does not heighten suggestibility. Inhibitory control and executive function are largely preserved, while motor coordination and cognitive flexibility decline modestly. These effects vary with metabolism, immune response, drug interactions, and context, underscoring the need for personalized monitoring. It is inferred that, acutely, positive affect may enhance therapeutic alliance and openness as well as susceptibility to boundary violations; amnestic effects may support trauma processing by facilitating fear extinction and disrupting negative memory reconsolidation; whereas temporary reductions in attention and cognitive flexibility may call for structured, emotionally focused therapeutic settings. MDMA's distinct neurocognitive profile offers clinical promise but complicates trial design by compromising blinding and inflating expectancy, necessitating their quantitative assessments and inclusion of similar comparator drugs to ensure reliable evaluation of efficacy.
Research Summary of 'Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use'
Blossom's Take
One of the criticisms around the rejection of the FDA application of MDMA-assisted therapy (Lykos/Resillience) was the lack of measurements on positive (adverse) effects. This review offers data (in healthy volunteers) on these effects. Though not revolutionary nor unexpected, it does provide scientific insight into how MDMA impacts participants in (clinical) studies.
Introduction
MDMA has a long and controversial history, moving from early chemical synthesis and military interest to therapeutic experimentation and later recreational use. Earlier work in heavy Ecstasy users raised concerns about possible serotonergic neurotoxicity and subtle cognitive harms, but those findings were limited by cross-sectional designs, confounding, and uncertainty about whether changes reflected permanent damage or adaptation. At the same time, Phase II and Phase III trials of MDMA-assisted psychotherapy for PTSD suggested substantial symptom reductions, yet regulators have criticised the evidence base for issues including adverse-event reporting, durability of benefit, blinding, and expectancy bias. Ramaekers and colleagues therefore set out to summarise placebo-controlled single-dose studies of pharmaceutical MDMA in healthy volunteers, with a focus on acute and subacute subjective effects and neurocognitive effects that are relevant to therapeutic use. Their aim was to identify what MDMA does in controlled clinical settings, what factors modify its effects, and what these findings imply for safety, trial design, and MDMA-assisted psychotherapy. The paper is framed as a narrative review intended to bridge mechanistic findings from healthy volunteers with clinical considerations for PTSD treatment.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Authors
- APA Citation
Ramaekers, J. G., Kuypers, K. P. C., & Vollenweider, F. X. (2026). Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use. Molecular Psychiatry. https://doi.org/10.1038/s41380-026-03602-7
References (58)
Papers cited by this study that are also in Blossom
Benzenhöfer, U., Passie, T. · Addiction (2010)
Passie, T., Benzenhöfer, U. · Journal of Psychoactive Drugs (2016)
Vegting, Y., Reneman, L., Booij, J. · Psychopharmacology (2016)
Roberts, C. A., Quednow, B. B., Montgomery, C. et al. · Neuroscience and Biobehavioral Reviews (2017)
Bouso, J. C., Doblin, R., Farré, M. et al. · Journal of Psychoactive Drugs (2008)
Feduccia, A. A., Mithoefer, M. C. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Mitchell, J., Ot’alora G, M., van der Kolk, B. et al. · Nature Medicine (2023)
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2010)
Montgomery, C., Roberts, C. A. · Experimental Neurology (2021)
Liechti, M. E., Baumann, C., Gamma, A. et al. · Neuropsychopharmacology (2000)
Show all 58 referencesShow fewer
Dunlap, L. E., Andrews, A. M. · ACS Chemical Neuroscience (2018)
Studerus, E., Vizeli, P., Harder, S. et al. · Journal of Psychopharmacology (2021)
Vizeli, P., Liechti, M. E. · Journal of Psychopharmacology (2017)
Kirkpatrick, M. G., Francis, S. M., Lee, R. et al. · Psychoneuroendocrinology (2014)
Hysek, C. M., Liechti, M. E. · Psychopharmacology (2012)
Straumann, I., Ley, L., Holze, F. et al. · Neuropsychopharmacology (2023)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Kirkpatrick, M. G., Delton, A. W., de Wit, H. et al. · Journal of Psychopharmacology (2015)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Papaseit, E., Pérez-Mañá, C., Mateus, J. A. et al. · Neuropsychopharmacology (2016)
Vizeli, P., Liechti, M. E. · PLOS ONE (2018)
Dolder, P. C., Müller, F., Schmid, Y. et al. · Psychopharmacology (2017)
Bershad, A. K., Schepers, S. T., Bremmer, M. P. et al. · Biological Psychiatry (2019)
Schmid, Y., Schmidt, A., Müller, F. et al. · International Journal of Neuropsychopharmacology (2017)
Bershad, A. K., Hsu, D. T., De Wit, H. · Journal of Psychopharmacology (2024)
Vizeli, P., Straumann, I., Duthaler, U. et al. · Frontiers in Pharmacology (2022)
Baggot, M. J., Kirkpatrick, M. G., Bedi, G. et al. · Journal of Psychopharmacology (2015)
Gabay, A. S., Carhart-Harris, R. L., Mazibuko, N. et al. · Scientific Reports (2018)
Liechti, M. E., Gamma, A., Vollenweider, F. X. · Psychopharmacology (2001)
Dipasquale, O., Selvaggi, P., Veronese, M. et al. · NeuroImage (2019)
Hasler, F., Ludewig, S. · Journal of Psychopharmacology (2008)
Sessa, B. · Neuroscience Letters (2016)
Zeifman, R. J., Kettner, H., Ross, S. et al. · European Journal of Psychotraumatology (2024)
Agin-Liebes, G. I., Zeifman, R. J., Mitchell, J. · European Journal of Psychotraumatology (2025)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Colcott, J., Guerin, A. A., Carter, O. et al. · Neuropsychopharmacology (2024)
Kuypers, K. P. C., Ramaekers, J. G. · Journal of Psychopharmacology (2005)
Kuypers, K. P. C., Ramaekers, J. G. · Psychopharmacology (2006)
Kuypers, K. P. C., Theunissen, E. L., de Sousa Fernandes Perna, E. B. et al. · PLOS ONE (2016)
Kloft, L., Otgaar, H., Blokland, A. et al. · European Neuropsychopharmacology (2022)
Sarmanlu, M., Kuypers, K. P. C., Vizeli, P. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2023)
Maples-Keller, J. L., Norrholm, S. D., Burton, M. et al. · Journal of Psychopharmacology (2022)
Doss, M. K., Weafer, J. J., Gallo, D. A. et al. · Neuropsychopharmacology (2017)
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D. et al. · International Journal of Neuropsychopharmacology (2013)
Ramaekers, J. G., Kuypers, K. P. C. · Neuropsychopharmacology (2005)
Downing, J. · Journal of Psychoactive Drugs (1986)
Wagner, M. T., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychopharmacology (2017)
Vizeli, P., Schmid, Y., Prestin, K. et al. · European Neuropsychopharmacology (2017)
Vizeli, P., Meyer Zu Schwabedissen, H. E., Liechti, M. E. · ACS Chemical Neuroscience (2018)
Jerome, L., Feduccia, A. A., Wang, J. B. et al. · Psychopharmacology (2020)
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)
Szigeti, B., Nutt, D. J., Carhart-Harris, R. L. et al. · Scientific Reports (2023)
Poyatos, L., Lo Faro, A., Sprega, G. et al. · International Journal of Molecular Sciences (2022)
Ramaekers, J. G., Reckweg, J., Mason, N. L. et al. · Neuropsychopharmacology (2024)
Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)
Schmidt, E. F., Warner-Schmidt, J., Stogniew, M. et al. · Frontiers in Neuroscience (2024)
Jones, A., Warner-Schmidt, J., Kwak, H. et al. · JAMA Psychiatry (2026)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.